Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

By P. Kantoff, Celestia S. Higano, N. Shore, E. Berger, E. Small, D. Penson, C. Redfern, A. Ferrari, R. Dreicer, R. Sims and 3 more. New England Journal of Medicine, 2010

5,378 citations recorded by the source corpus.

Subfields: Immunology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/239c572c328e3bbb0f025fc069fb97f9e5ba78d5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. S. Rosenberg
2. T. Gajewski
3. N. Restifo
4. M. Dudley
5. K. Palucka
6. S. Spranger
7. L. Zitvogel
8. Jacques Banchereau

In Pulmonary and Respiratory Medicine

1. M. Hallek
2. J. O’Sullivan
3. Celestia S. Higano
4. M. Cheever
5. Eleftherios P. Diamandis

Citations in the corpus

• Genetics and biology of prostate cancer (2018, background): “To date, the FDA-approved dendritic cell-based cancer vaccine sipuleucel-T has shown only modest survival benefit (Kantoff et al. 2010), and clinical trials with immune checkpoint inhibitors (e.”
• Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011, neutral): “Bone pain 194 (25) 42 (5) 2 (<1) 110 (28) 25 (6) 4 (1)”
• Systemic Immunity is Required for Effective Cancer Immunotherapy (2017, positive): “In contrast, dendritic cell vaccines can stimulate de novo T cell responses and have shown efficacy (Kantoff et al., 2010).”
• Cancer immunotherapy via dendritic cells (2012, neutral): “gov/drugdictionary?CdrID=38038">sipuleucel-T (also known as APC 8015), which is a cellular product based on enriched blood APCs that are briefly cultured with a fusion protein of prostatic acid phosphatase (PAP) and GM-CSF, resulted in an approximately 4-month-prolonged median survival in Phase III”
• Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. (2017, background): “clinical activity of sipuleucel-T, a cellular immunotherapy based on ex vivo–activated peripheral mononuclear cells.(11-16) Ipilimumab is a fully human monoclonal immunoglobulin G1 antibody that increases antitumor T-cell responses by binding to.”
• Cancer immunotherapy: the beginning of the end of cancer? (2016, background): “(GM-CSF), achieved an approximately 4-month improvement in median survival [18, 19].”
• Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells (2013, background): “…has been observed in the case of interleukin-2 (IL-2) for melanoma and kidney cancer (1), experimental cancer vaccines (2), and the recently U.S. Food and Drug Administration–approved agents Provenge for prostate cancer (3) and anti– CTLA-4 monoclonal antibody (mAb) (ipilimumab) for melanoma (4).”
• Regulation of PD-L1: a novel role of pro-survival signalling in cancer. (2016, background): “These include administration of immune-stimulating cytokines such as interferon (IFN) and interleukin-2, active immunization to enhance endogenous immune responses such as dendritic cell (DC)-based vaccination, adoptive cell-transfer therapy using autologous cancer-specific cytotoxic T-cells (CTLs) ”